An interventional study of Pleuroscopy first and Thoracentesis first in Pleural Effusion and Cancer, sponsored by Icahn School of Medicine at Mount Sinai. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Pleural Effusion with a site in United States — 6 open to participants now, 9 under way, none of them phase 3. Pleural Effusion · United States.
Among the 45 studies in Pleural Effusion with a site in United States, this one is the 15th largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2025, is one of 18 with no phase, and was the 41st registered.
241 studies on the registry are indexed under Pleural Effusion; 49 are open to participants now.
Browse Pleural Effusion studies →6 of the 45 studies in Pleural Effusion with a site in United States are open now. Recruiting first, the newest first:
Albany Medical College · Sites in United States
Ages 18+
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18+
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18+
University of Arizona · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Pleural Effusion studies recruiting now, 25 (83%) set no upper age limit and 2 (7%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 3 · Phase 4 3
First in 2000; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is close to the median of 80 across 142 interventional studies indexed under Pleural Effusion.
Median enrollment 42 across the 34 interventional studies, 200 across the 11 observational. Of the 32 that completed or were terminated, 11 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 45 have an industry lead sponsor. The 10 most frequent:
Icahn School of Medicine at Mount Sinai is the lead sponsor of 776 studies on the registry; 175 are open to participants now.
Of its 125 completed or terminated interventional studies of FDA-regulated products, 83 (66%) have results posted.
Icahn School of Medicine at Mount Sinai has 2 studies filed under Pleural Effusion — fewer than ten, so there is no comparison to draw.
4 of the studies in Pleural Effusion with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06538376Brigham and Women's HospitalClinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU | 2026-11 |
| NCT03831386Johns Hopkins UniversityGravity Versus Vacuum Based Indwelling Tunneled Pleural Drainage System | 2026-12-31 |
| NCT07929584University of ArizonaA Study to Establish the Diagnostic Value of the EPISEEK-MPE Liquid Biopsy Assay to Identify Cancer in Pleural Effusion Samples. | 2026-12-31 |
| NCT06727578Beth Israel Deaconess Medical CenterPleural Irrigation With a Novel Devise. | 2027-05-25 |
Add all 4 to your calendar (.ics) → With an account.
Among the 45 studies in Pleural Effusion with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized control trial of patients with suspected malignant pleural effusions to compare whether patients who have a thoracentesis or pleuroscopy (pleural biopsy) obtain an adequate biopsy, achieve a diagnosis, and begin cancer-directed therapy faster.
This is a randomized control trial of patients with suspected malignant pleural effusions comparing patients who undergo either pleuroscopy or thoracentesis as the first diagnostic test. Both procedures are considered standard of care for this diagnosis but it is unknown which one provides more adequate biopsy samples and achieves faster diagnosis and shorter time to oncologic treatment. Currently, most patients undergo thoracentesis first and, if this is inadequate for diagnosis, they then undergo pleuroscopy for further biopsy samples. This study seeks to assess whether patients who undergo pleuroscopy as the first test obtain adequate biopsy samples and a faster path to further oncologic care compared to patients who undergo thoracentesis first. Patients will be recruited and randomized in a 1:1 manner.
Ultrasound is routinely used prior to the procedure and a chest x-ray is done after the procedure. Any other imaging will be determined by clinic need only. No imaging will be done for research purposes. No additional samples will be collected other than what is necessary for diagnostic purposes. In patients who have a non-diagnostic thoracentesis, the participants will be referred for pleuroscopy as the next diagnostic step. In the rare case that pleuroscopy does not achieve adequate diagnosis, the next step would be a liquid biopsy (non-invasive serologic testing for oncologic markers.) The need for liquid biopsy in participants in this study will be determined on a case-by-case basis depending on the clinical concern for malignancy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo pleuroscopy first
Procedure: Pleuroscopy first
Participants will undergo thoracentesis first
Procedure: Thoracentesis first
Pleuroscopies are performed under moderate sedation with local anesthesia. Through a 1-cm incision a camera is introduced into the pleural space and the space is inspected after draining all fluid. Targeted biopsies under direct visualization are obtained using forceps. The aspirated fluid and biopsies obtained are sent to the cytology and pathology laboratories for analysis.
Thoracenteses are performed under local anesthesia with the insertion of a 5-8Fr catheter into the pleural space. The aspirated fluid obtained is sent to the cytology laboratory for analysis.
Proportion of biopsies adequate for definitive diagnosis
Proportion of biopsies adequate for definitive diagnosis
Time frame: 6 months
Time from initial visit with pulmonologist to procedure
Time from initial visit with pulmonologist to procedure
Time frame: 6 months
Time from initial procedure to diagnosis
Time from initial procedure to diagnosis
Time frame: 6 months
Time from initial visit with pulmonologist to diagnosis
Time from initial visit with pulmonologist to diagnosis
Time frame: 6 months
Time from initial visit with pulmonologist to seeing oncologist
Time from initial visit with pulmonologist to seeing oncologist
Time frame: 6 months
Time from initial visit with pulmonologist to starting treatment
Time from initial visit with pulmonologist to starting treatment
Time frame: 6 months
Time from seeing oncologist to starting treatment
Time from seeing oncologist to starting treatment
Time frame: 6 months
Frequency of procedure-related complications
Frequency of procedure-related complications
Time frame: 6 months
Frequency of additional diagnostic testing
Frequency of additional diagnostic testing
Time frame: 6 months
Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Immediately following publication. No end date.
Access criteria: Investigators whose proposed use of the data has been approved by an independent review committee ('learned intermediary') identified for this purpose. Any purpose. Proposals should be directed to udit.chaddha@mssm.edu. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years at a third party website (Link tbd).
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in Aug 2026, 17 months.
Of 61 non-industry interventional studies with no phase under Pleural Effusion, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 52. This study's 17 months is below that.
Counting every sponsor, half of 63 studies reached it within 26 months; a quarter within 16 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Sep 2026 → Aug 2026 and completion Sep 2026 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Icahn School of Medicine at Mount Sinai →